2.14
+0.27(+14.44%)
Currency In USD
| Previous Close | 1.87 |
| Open | 1.85 |
| Day High | 2.23 |
| Day Low | 1.85 |
| 52-Week High | 3.3 |
| 52-Week Low | 0.53 |
| Volume | 5.52M |
| Average Volume | 7.33M |
| Market Cap | 19.52M |
| PE | -1.03 |
| EPS | -2.07 |
| Moving Average 50 Days | 1.43 |
| Moving Average 200 Days | 0.97 |
| Change | 0.27 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of November 15, 2025 at a share price of $2.14. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.82 as of November 15, 2025 at a share price of $2.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
GlobeNewswire Inc.
Oct 28, 2025 12:45 PM GMT
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108 in ulcerative colitis and fibros
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
GlobeNewswire Inc.
Oct 20, 2025 12:45 PM GMT
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing development of PALI-2108 across fibrostenotic Croh
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
GlobeNewswire Inc.
Oct 13, 2025 12:45 PM GMT
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA, Oct. 13, 2025 (GLOBE NEWSWIRE)